A combination vinorelbine-estramustine in patients with hormone refractory prostate cancer

被引：0
|
作者：
Butera, A. [1 ]
Tornabene, P. [1 ]
机构：
[1] UO Oncol Med AOS Giovanni Dio Agrigento, Vicenza, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：82 / 82
页数：1
相关论文
共 50 条
  • [21] ORAL VINORELBINE (VRL) IN COMBINATION WITH ESTRAMUSTINE MONOPHOSPHATE (EMP) IN HORMONE-REFRACTORY PROSTATE CANCER (HRPC). RESULTS OF RETROSPECTIVE MONOCENTRIC EXPERIENCE AT CURIE INSTITUTE
    Beuzeboc, P.
    Pontvert, D.
    Cosset, J. M.
    Flam, T.
    Zerbib, M.
    Debre, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 200 - 200
  • [22] Hoosier oncology group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis
    Hahn, Noah M.
    Marsh, Sharon
    Fisher, William
    Langdon, Robert
    Zon, Robin
    Browning, Mark
    Johnson, Cynthia S.
    Scott-Horton, Tiffany J.
    Li, Lang
    McLeod, Howard L.
    Sweeney, Christopher J.
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6094 - 6099
  • [23] Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
    Soga, Norihito
    Kato, Manabu
    Nishikawa, Kouhei
    Hasegawa, Yoshihiro
    Yamada, Yasushi
    Kise, Hideaki
    Arima, Kiminobu
    Sugimura, Yoshiki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (02) : 130 - 135
  • [24] The use of paclitaxel, estramustine, and etoposide in the treatment of patients with hormone-refractory prostate cancer
    Pienta, KJ
    Smith, DC
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 51 - 51
  • [25] Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
    Norihito Soga
    Manabu Kato
    Kouhei Nishikawa
    Yoshihiro Hasegawa
    Yasushi Yamada
    Hideaki Kise
    Kiminobu Arima
    Yoshiki Sugimura
    International Journal of Clinical Oncology, 2009, 14 : 130 - 135
  • [26] Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer
    Matsumoto, Akihiro
    Inoue, Atsushi
    Yokoi, Satoshi
    Nozumi, Kazuyoshi
    Miyazaki, Kanetaka
    Hosoki, Shigeru
    Nagata, Maki
    Yamaguchi, Kunio
    INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (08) : 687 - 691
  • [27] Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: A pilot study
    Kuruma, H
    Fujita, T
    Shitara, T
    Egawa, S
    Yokoyama, E
    Baba, S
    INTERNATIONAL JOURNAL OF UROLOGY, 2003, 10 (09) : 470 - 475
  • [28] Oral estramustine and oral etoposide for hormone-refractory prostate cancer
    Dimopoulos, MA
    Panopoulos, C
    Bamia, C
    Deliveliotis, C
    Alivizatos, G
    Pantazopoulos, D
    Constantinidis, C
    Kostakopoulos, A
    Kastriotis, I
    Zervas, A
    Aravntinos, G
    Dimopoulos, C
    UROLOGY, 1997, 50 (05) : 754 - 758
  • [29] Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer
    Pienta, KJ
    Smith, DC
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 72 - 77
  • [30] Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer
    Segawa T.
    Kamoto T.
    Kinoshita H.
    Kunishima Y.
    Yoshimura K.
    Ito A.
    Takahashi T.
    Higashi S.
    Nakamura E.
    Nishiyama H.
    Ito N.
    Yamamoto S.
    Habuchi T.
    Ogawa O.
    International Journal of Clinical Oncology, 2005, 10 (5) : 333 - 337
12345